Christopher M. Brackett

Christopher M. Brackett

Auto-generated profile, based on publicly available information

Christopher M. Brackett

South University School of Pharmacy Savannah Giorgia USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
CBChristopher M. Brackett
Christopher M. Brackett
Brian BlaggBrian Blagg
Brian Blagg
SUMOylation has emerged as an important post-translational modification that involves the covalent attachment of the Small Ubiquitin-like Modifier (SUMO) polypeptide to a lysine residue of a target protein. The enzymatic pathway of SUMOylation is very similar to ubiquitinylation and involves an activating enzyme, a conjugating enzyme, ligases, and deconjugating enzymes. SUMOylation modulates the function of a number of proteins associated with various pathways, and in fact, dysregulation of the SUMOylation pathway is observed in both cancer and neurological diseases. In many cancers, the SUMO enzymes are upregulated, and SUMO levels correlate directly with prognosis and disease progression. As a result, there has been an emphasis on the discovery and development of inhibitors of SUMOylation. In this review, the latest advances in SUMOylation inhibitors are described alongside the methods used to discover small molecule SUMOylation inhibitors, which include natural products, peptidomimetics, as well as synthetic derivatives identified via virtual screens.

21 July 2022 in Medicinal Research Reviews
Verified
Journal Article
Closed access
KPKyler W. Pugh
Kyler W. Pugh
MAMarim Alnaed
Marim Alnaed
CBChristopher M. Brackett
Christopher M. Brackett
Brian BlaggBrian Blagg
Brian Blagg

19 April 2019 in ACS Infectious Diseases
Verified
Journal Article
Open access
SMSara E. Martin
Sara E. Martin
RMRoberta Melander
Roberta Melander
CBChristopher M. Brackett
Christopher M. Brackett
ASAlison J. Scott
Alison J. Scott
CCCourtney E. Chandler
Courtney E. Chandler
CMChristian Corey Melander
Christian Corey Melander
In 2016, the World Health Organization deemed antibiotic resistance one of the biggest threats to global health, food security, and development. The need for new methods to combat infections caused by antibiotic resistant pathogens will require a variety of approaches to identifying effective new therapeutic strategies. One approach is the identification of small molecule adjuvants that potentiate the activity of antibiotics of demonstrated utility, whose efficacy is abated by resistance, both acquired and intrinsic. To this end, we have identified compounds that enhance the efficacy of antibiotics normally ineffective against Gram-negative pathogens because of the outer membrane permeability barrier. We identified two adjuvant compounds that dramatically enhance sensitivity of Acinetobacter baumannii to macrolide and glycopeptide antibiotics, with reductions in minimum inhibitory concentrations as high as 256-fold, and we observed activity across a variety of clinical isolates. Mode of action studies indicate that these adjuvants likely work by modulating lipopolysaccharide synthesis or assembly. The adjuvants were active in vivo in a Galleria mellonella infection model, indicating potential for use in mammalian infections.

12 January 2025 in Drug Development Research
Verified
Journal Article
Closed access
LDLaura D'ALessio‐Sands
Laura D'ALessio‐Sands
JGJoshua Gaynier
Joshua Gaynier
VMVictoria Michel‐Milian
Victoria Michel‐Milian
AAAyodeji A. Agbowuro
Ayodeji A. Agbowuro
CBChristopher M. Brackett
Christopher M. Brackett